We use cookies to make your experience better. To comply with the new e-Privacy directive, we need to ask for your consent to set the cookies. Learn more.
ACCELERATE YOUR COVID-19 RESEARCH WITH OUR PRODUCTS CATALOG
SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) also known as 2019 nCoV (2019 Novel Coronavirus) represents a pandemic threat that has been declared a public health emergency of international concern by WHO, mobilizing the actors of all the fields to find new means to fight against this virus, in particular in the field of research.
Covalab is making all the effort to help you in your research by offering wide range of tools such as specific proteins from SARS-Cov-2, antibodies or immunoassays involved in the metabolic pathways of infection, to accelerate the research, diagnostic and treatment of COVID-19.
2019 nCoV is an enveloped, single, and positive-stranded RNA virus. The virus encodes four major structural proteins that have played important roles in causing the infection (*): Spike protein (S protein), nucleocapsid protein (N protein), membrane protein (M protein), and small envelope protein (E protein) (Fig.1).
S protein is a large type I transmembrane protein, composed of two sub-units S1 and S2. S protein is essential for both host specificity and viral infectivity.
For viral entry, the S1 sub-unit binds via its RBD (Receptor Binding Domain) to the cellular receptor angiotensin-converting enzyme 2 (ACE2) and after cleavage by proteases (Furin and TMPRSS2), the active S2 sub-unit fuses to the viral membranes with the host cell membrane. The spike protein is reported to induce the neutralizing-antibody and T-cell responses, as well as protective immunity. The CoV spike (S) glycoprotein therefore represent the key target for vaccines, therapeutic antibodies, and diagnostics (*).
SARS-Cov-2 can be triggered to fuse at either the plasma membrane or the endosomal membrane, and the route of entry is dependent on protease availability (Fig. 2).
The virus antigens are presented to the immune-system (APCs, macrophage, …) which in turn produce a range of pro- inflammatory "cytokines” (e.g. IL6, IFNα, IFNβ, IFNγ, IFNλ…) and TNF-α (*). In some cases, these cytokines proliferate and activate an uncontrolled and devastating pro-inflammatory response in the host.
Coronavirus Research Products:
For all information about these following products, contact us at contact@covalab.com
Recombinant Proteins
Coming soon : our lab is finalizing the production of SARS-CoV-2 protein variants
- RBD protein : UK (N501Y & E484K-N501Y) ; South Africa (K417N-E484K-N501Y) ; Brazil (K417T-E484L-N501Y) ; California (L452R)
- N protein : D3L-S235F ; D3L-R203K-G204R-S235F
- S1 protein : K417N-E484K-N501Y - D614G
| Recombinant Spike Protein | |||
| Description | Packaging | #Catalog | Price |
|
Soluble Spike - HEK / E.coli Recombinant soluble Spike (S) protein (ECD), amino acids 13-1213 C-terminal hexa-His-Tag (HEK cells) or N-terminal GST, C-terminal hexa-His-Tag (E.Coli).
CURRENTLY UNDER VALIDATION |
100 µg | Contact us | |
|
SARS-CoV-2 recombinant Spike (S) protein S1-Subunit, amino acids 13-685, C-terminal hexa-His-Tag (HEK cells). |
100 µg | CovID190002 | 449€ |
|
Variant S1-Subunit (K417N-E484K-N501Y - D614G)
Variant SARS-CoV-2 recombinant Spike (S) protein S1-Subunit, mutation K417N-E484K-N501Y - D614G, C-terminal hexa-His-Tag (HEK cells) |
100 µg | Contact us | |
|
SARS-CoV-2 recombinant Spike (S) protein S1-Subunit, amino acids 13-685, N-terminal GST, C-terminal hexa-His-Tag (E.Coli). |
100 µg | CovID190004 | 449€ |
|
SARS-CoV-2 recombinant Spike (S) protein (receptor-binding domain, RBD), amino acids 319-541, C-terminal hexa-His-Tag (HEK cells) or N-terminal GST, C-terminal hexa-His-Tag (E.Coli). |
100 µg | CovID190003 | 449€ |
| 1 mg | CovID190003 | Contact us | |
|
SARS-CoV-2 recombinant Spike (S1) protein (receptor-binding domain, RBD), amino acids 319-541, C-terminal hexa-His-Tag (CHO cells).
|
100 µg | pro30004 | 498€ |
|
RBD - UK Variant (N501Y & E484K-N501Y) UK Variant SARS-CoV-2 recombinant Spike RBD protein, mutation N501Y & E484K-N501Y, C-terminal hexa-His-Tag (HEK cells) |
100 µg | Contact us | |
|
RBD - South Africa Variant (K417N-E484K-N501Y) South Africa Variant SARS-CoV-2 recombinant Spike RBD protein, mutation K417N-E484K-N501Y, C-terminal hexa-His-Tag (HEK cells) |
100 µg | Contact us | |
|
RBD - Brazil Variant (K417T-E484L-N501Y)
Brazil Variant SARS-CoV-2 recombinant Spike RBD protein, mutation K417N-E484K-N501Y, C-terminal hexa-His-Tag (HEK cells) |
100 µg | Contact us | |
|
RBD - California Variant (L452R)
California Variant SARS-CoV-2 recombinant Spike RBD protein, mutation L452R, C-terminal hexa-His-Tag (HEK cells) |
100 µg | Contact us | |
|
Recombinant Spike (S) protein (S2 ECD), amino acids 686-1213, C-terminal hexa-His-Tag (HEK cells). |
100 µg | CovID190008 | Contact us |
|
Spike protein (ECD, His & Flag Tag) - Sf9 insect cells |
100 µg | Contact us | |
 |
 |
 |
|
WB: Recombinant Virus SARS-CoV-2 Spike protein S1 subunit - HEK293 - his tag (lane 1, 0.5 µg, ref: CovID190002), Spike protein (RBD) - HEK293 - His tag (lane 2, 0.5 µg, ref: CovID190003), and RBD competitor (lane 3, 0.5 µg), showing a glycosylated band at 130 kDa and 34 kDa respectively. Antibodies dilution: Primary SARS‑CoV-2 Spike - S1 subunit Antibody (27H7) (1000e, ref: mab0163-P) and secondary anti-anti-His Tag (HIS.H8 / EH158) (1mg/ml, ref: mab90001-P). |
SDS-PAGE: Recombinant Virus SARS-CoV-2 Spike protein S1 subunit - HEK293 - his tag (lane 1, 2µg, ref: CovID190002), Spike protein (RBD) - HEK293 - His tag (lane 2, 2µg, ref: CovID190003), and RBD competitor (lane 3, 2µg), analyzed by SDS-PAGE (7,5% gel) with Coomassie Blue, showing a glycosylated band at 130 kDa and 34 kDa respectively. |
ELISA: Immunoreactivity validation by ELISA test using coated Spike protein S1 subunit – HEK – his tag (ref: CovID190002) and Spike protein (RBD) – HEK – His tag (ref: CovID190003). Antibodies dilution: Primary SARS‑CoV‑2 Spike-RBD domain antibody (ref: pab01035-P) and secondary anti-rabbit HRP (2000e, ref: lab0252). |
| Recombinant E protein | |||
| Description | Packaging | #Catalog | Price |
|
Protein E - HEK / E.coli SARS CoV-2 recombinant E protein, amino acids 1-75, C-terminal hexa-His-Tag (HEK cells) or N-terminal GST, C-terminal hexa-His-Tag (E.Coli).
CURRENTLY UNDER VALIDATION |
100 µg | Contact us | |
| Recombinant N protein | |||
| Description | Packaging | #Catalog | Price |
|
SARS-CoV-2 recombinant N protein, amino acids 1-419, C-terminal hexa-His-Tag (HEK cells). |
100 µg | CovID190001 | 449€ |
|
SARS-CoV-2 recombinant N protein, amino acids 1-419, C-terminal hexa-His-Tag (E.Coli). |
100 µg | CovID190007 | 449€ |
|
Variant Nucleoprotein (D3L-S235F) Variant SARS-CoV-2 recombinant Nucleoprotein, mutation D3L-S235F, C-terminal hexa-His-Tag (HEK cells) |
100 µg | Contact us | |
|
Variant Nucleoprotein (D3L-R203K-G204R-S235F)
Variant SARS-CoV-2 recombinant Nucleoprotein, mutation Variant SARS-CoV-2 recombinant Nucleoprotein, mutation D3L-S235F, C-terminal hexa-His-Tag (HEK cells), C-terminal hexa-His-Tag (HEK cells) |
100 µg | Contact us | |
| Recombinant M protein | |||
| Description | Packaging | #Catalog | Price |
|
Membrane protein (M) – HEK / E.Coli SARS CoV-2 recombinant M protein, amino acids 1-222, C-terminal hexa-His-Tag (HEK cells) or N-terminal GST, C-terminal hexa-His-Tag (E.Coli).
CURRENTLY UNDER VALIDATION |
100 µg | Contact us | |
| Recombinant ACE-2 protein | |||
| Description | Packaging | #Catalog | Price |
|
Recombinant ACE2 protein (ACE2), amino acids 19-7615, C-terminal hexa-His-Tag (HEK cells). |
100 µg | pro30005 | 449€ |
|
ACE-2 Fc Chimera, Human |
100 µg | Contact us | |
Antibodies
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Immunoassays
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Peptides
Thanks to our expertise in the fields of peptide design, synthesis and modification, we provide a high-quality peptide synthesis service, including a wide range of chemical modifications.
In addition, we offer a specific peptide library for research on SARS-CoV-2 form crude, >70% to very hight purity (>98%).
| Protein name | Lenght | Uniprot ID |
| SARS-CoV-2 Spike Glycoprotein | 1 273 aa | P0DTC2 |
| HCoV-229E Spike Glycoprotein | 1 173 aa | P15423 |
| SARS-CoV-2 N | 419 aa | P0DTC9 |
| SARS-CoV-2 E | 75 aa | P0DTC4 |
| SARS-CoV-2 M | 222 aa | P0DTC5 |
| SARS-CoV-2 ORF3a | 275 aa | P0DTC3 |
| and many others... | ||
Contact us for design and more information about peptide synthesis at enquiries@covalab.com.
All our team are available for all requests.